Complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets

Michelle Ojemuyiwa, Karen Zeman, Alexander Spira, Bryan Oronsky, Carolyn Ray, Jane B. Trepel, Min Jung Lee, Ifeyinwa Onyiuke, Christina Brzezniak

Research output: Contribution to journalArticlepeer-review

Abstract

Presented herein is the case of a heavily pretreated patient with high-grade neuroendocrine prostate cancer that achieved a complete metabolic response on platinum-based chemotherapy after treatment with the dual CD-47 and SIRP-α inhibitor, RRx-001, in a Phase II clinical trial.

Original languageEnglish (US)
Pages (from-to)2478-2481
Number of pages4
JournalClinical Case Reports
Volume6
Issue number12
DOIs
StatePublished - Dec 2018
Externally publishedYes

Keywords

  • RRx-001
  • macrophage repolarization
  • neuroendocrine cancer
  • platinum doublets
  • priming
  • prostate cancer

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets'. Together they form a unique fingerprint.

Cite this